Literature DB >> 35653599

Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684-691.

Juraj Koska1, Hertzel C Gerstein2, Paul J Beisswenger3, Peter D Reaven1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35653599      PMCID： PMC9210513          DOI： 10.2337/dci22-0013

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   17.152


× No keyword cloud information.
  9 in total

1.  Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress.

Authors:  Paul J Beisswenger; Keith S Drummond; Robert G Nelson; Scott K Howell; Benjamin S Szwergold; Michael Mauer
Journal:  Diabetes       Date:  2005-11       Impact factor: 9.461

2.  Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684-691.

Authors:  Gauthier Borderie; Alice Larroumet; Laurence Baillet-Blanco; Ninon Foussard; Vincent Rigalleau
Journal:  Diabetes Care       Date:  2022-06-02       Impact factor: 19.112

3.  Skin autofluorescence is associated with progression of kidney disease in type 2 diabetes: A prospective cohort study from the Hong Kong diabetes biobank.

Authors:  Qiao Jin; Eric Sh Lau; Andrea Oy Luk; Risa Ozaki; Elaine Yk Chow; Tammy So; Theresa Yeung; Kit-Man Loo; Cadmon Kp Lim; Alice Ps Kong; Wing Yee So; Alicia J Jenkins; Juliana Cn Chan; Ronald Cw Ma
Journal:  Nutr Metab Cardiovasc Dis       Date:  2021-10-23       Impact factor: 4.222

4.  Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus.

Authors:  T M Jensen; D Vistisen; T Fleming; P P Nawroth; P Rossing; M E Jørgensen; T Lauritzen; A Sandbaek; D R Witte
Journal:  Diabet Med       Date:  2016-08-25       Impact factor: 4.359

5.  Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications.

Authors:  Esther G Gerrits; Helen L Lutgers; Nanne Kleefstra; Reindert Graaff; Klaas H Groenier; Andries J Smit; Rijk O Gans; Henk J Bilo
Journal:  Diabetes Care       Date:  2007-11-26       Impact factor: 19.112

6.  Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.

Authors:  Carlos Abraira; William Duckworth; Madeline McCarren; Nicholas Emanuele; Danielle Arca; Domenic Reda; William Henderson
Journal:  J Diabetes Complications       Date:  2003 Nov-Dec       Impact factor: 2.852

7.  Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes.

Authors:  Juraj Koska; Hertzel C Gerstein; Paul J Beisswenger; Peter D Reaven
Journal:  Diabetes Care       Date:  2022-03-01       Impact factor: 19.112

8.  Advanced Glycation End Products Predict Loss of Renal Function and Correlate With Lesions of Diabetic Kidney Disease in American Indians With Type 2 Diabetes.

Authors:  Pierre-Jean Saulnier; Kevin M Wheelock; Scott Howell; E Jennifer Weil; Stephanie K Tanamas; William C Knowler; Kevin V Lemley; Michael Mauer; Berne Yee; Robert G Nelson; Paul J Beisswenger
Journal:  Diabetes       Date:  2016-09-08       Impact factor: 9.461

9.  Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products.

Authors:  Paul J Beisswenger; Scott K Howell; Gregory B Russell; Michael E Miller; Stephen S Rich; Michael Mauer
Journal:  Diabetes Care       Date:  2013-06-18       Impact factor: 19.112
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.